Delivery Order SPE2DB24D3013-SPE2DB26FFFRA
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of LUMAKRAS 320 mg tablets (90-count units) with a ceiling value of $13,491.97. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is scheduled for completion by October 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a $13,491.97 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of LUMAKRAS 320 mg tablets (90-unit quantity). This competitive award, utilizing firm fixed pricing, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract involves no set-aside designation, with performance to be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for LUMAKRAS 320 mg tablets (90-count) with a ceiling value of $13,491.97. This firm fixed-price contract, issued on August 1, 2025, with an ultimate completion date of August 22, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for LUMAKRAS 320 mg tablets (90-count supply) on September 25, 2025, with a ceiling value of $13,491.97 and ultimate completion date of October 17, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award to the prime contractor at its corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $13,491.97 to AmerisourceBergen Drug Corp for 90 tablets of LUMAKRAS 320 mg, a prescription medication used in cancer treatment. This competitive award, issued on August 29, 2025, with an ultimate completion date of September 22, 2025, represents a firm fixed-price delivery order with no set-aside designation. The pharmaceutical will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen...
- This federal contract award is for the delivery of Lumakras 120 mg tablets to the Defense Logistics Agency (DLA). The $24,084.36 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on February 22, 2023. The contract has a completion date of March 15, 2023 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a Delivery Order with a firm fixed price of $13,491.97 and a performance period through June 30, 2025. The contract is for the delivery of LUMAKRAS 320 MG TABLET 90S, a pharmaceutical product. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a $13,491.97 firm fixed-price delivery order contract awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of LUMAKRAS 320 MG TABLET 90S, a pharmaceutical product, with a completion date of June 20, 2025. AmerisourceBergen Drug Corp is a for-profit organization and a significant vendor for the DLA, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) designated as SPE2DX to provide a wide...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of LUMAKRAS 320 MG TABLET 90S, a pharmaceutical product, with a ceiling value of $13,491.97 and a period of performance through May 16, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract...
- This federal contract award, with ID SPE2DB20D1100|SPE2DB25FC0C0, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,491.97 firm fixed-price delivery order is for the supply of 4,568,075,826 units of the drug LUMAKRAS 320 MG TABLET 90S. The contract has a completion date of May 20, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB26FFFRADelivery Order
The Defense Logistics Agency (DLA) awarded a Delivery Order valued at $13,491.97 to AmerisourceBergen Drug Corp for the supply of Lumakras 120 mg tablets (240 count). The contract, awarded on October 17, 2025, with an ultimate completion date of November 7, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, supplying military and veteran healthcare systems with an extensive portfolio of medications, vaccines, medical devices, and specialized healthcare commodities. The company's significant presence within the DLA's Medical Supply Chain reflects its capability to fulfill federal medical supply requirements through open competition. This contract supports the Defense Health Agency and other government healthcare systems by delivering specialty pharmaceutical products essential to military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.5k | 10/17/25 |